ArticlePhotochemistry and photobiology2019
A Combination of Visudyne and a Lipid-anchored Liposomal Formulation of Benzoporphyrin Derivative Enhances Photodynamic Therapy Efficacy in a 3D Model for Ovarian Cancer.
Article in Photochemistry and photobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 79 citations in OpenAlex.
- Novel BODIPY-Loaded Liposomes Enhance Cellular Uptake and PDT Efficacy in 2D and 3D Models.Pharmaceutics · 2026Article
- Redox-modulation of regulated cell death: implications for synergistic anticancer therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- The clinical ionizable lipid SM-102 enhances photochemical immunogenic cell death by verteporfin-conjugated liposomes and improves survival in vivo.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Cancer-selective photoimmunotherapy spares T cells and NK cells and promotes antitumor immunity in an allogeneic human 3D culture model.Photochemistry and photobiology · 2026Article
- Sub-50-femtosecond gain-managed amplified pulses enhance nonlinear ablation efficiency.Biomedical optics express · 2026Article
- Photodynamic priming enhances anti-PD1 therapy responses in patient-derived pancreatic cancer organoid immune cocultures.Frontiers in immunology · 2026Article
- Beyond light scattering: the effects of intralipid on benzoporphyrin derivative-sensitized photodynamic treatment in ovarian cancer cells.Journal of biomedical optics · 2025Article
- Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment.Pharmaceutics · 2025Review
- Advancements in nanotechnology-driven photodynamic and photothermal therapies: mechanistic insights and synergistic approaches for cancer treatment.RSC advances · 2024Review
- Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma.Advanced nanobiomed research · 2024Article
- Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study.British journal of cancer · 2024Article
- Engineering photodynamics for treatment, priming and imaging.Nature reviews bioengineering · 2024Article
- A BODIPY-Naphtholimine-BFJACS Au · 2024Article
- A Physiochemical,ACS applied bio materials · 2024Article
- Targeting Mitochondria for Cancer Treatment.Pharmaceutics · 2024Review
- Micro- and Nanomanufacturing for Biomedical Applications and Nanomedicine: A Perspective.Small science · 2023Article
- Combination of Two Photosensitisers in Anticancer, Antimicrobial and Upconversion Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Photochemical Targeting of Mitochondria to Overcome Chemoresistance in Ovarian CancerPhotochemistry and photobiology · 2023Review
- Photodynamic Priming Overcomes Per- and Polyfluoroalkyl Substance (PFAS)-Induced Platinum Resistance in Ovarian CancerPhotochemistry and photobiology · 2023Article
- Spotlight on Photoactivatable Liposomes beyond Drug Delivery: An Enabler of Multitargeting of Molecular Pathways.Bioconjugate chemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
A major objective in developing new treatment approaches for lethal tumors is to reduce toxicity to normal tissues while maintaining therapeutic efficacy. Photodynamic therapy (PDT) provides a mechanistically distinct approach to treat tumors without the systemic toxicity of chemotherapy drugs. PDT involves the light-based activation of a small molecule, a photosensitizer (PS), to generate reactive molecular species (RMS) that are toxic to target tissue. Depending on the PS localization, various cellular and subcellular components can be targeted, causing selective photodamage. It has been shown that targeted lysosomal photodamage followed by, or simultaneous with, mitochondrial photodamage using two different PS results in a considerable enhancement in PDT efficacy. Here, two liposomal formulations of benzoporphyrin derivative (BPD): (1) Visudyne (clinically approved) and (2) an in-house formulation entrapping a lipid conjugate of BPD are used in combination with direct PS localization to mitochondria, endoplasmic reticulum and lysosomes, enabling simultaneous photodamage to all three organelles using a single wavelength of light. Building on findings by our group, and others, this study demonstrates, for the first time in a 3D model for ovarian cancer, that BPD-mediated photodestruction of lysosomes and mitochondria/ER significantly enhances PDT efficacy at lower light doses than treatment with either PS formulation alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.